BiotechTube
CatalYm

CatalYm

Martinsried, Germany· Est.
catalym.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $200M

Overview

CatalYm is a clinical-stage biotech focused on overcoming cancer therapy resistance by neutralizing GDF-15 (Growth Differentiation Factor-15), a key immunosuppressant hijacked by tumors. The company's lead asset, visugromab, has demonstrated durable objective responses in Phase 1/2a trials in checkpoint inhibitor-refractory metastatic solid tumors. With an experienced leadership team, CatalYm is now expanding its clinical program into Phase 2b studies in non-small cell lung cancer (NSCLC) and other indications, positioning visugromab as a potential backbone combination therapy in immuno-oncology.

OncologyImmuno-oncology

Technology Platform

Platform focused on neutralizing GDF-15 (Growth Differentiation Factor-15), a key immunosuppressant in the tumor microenvironment, using monoclonal antibodies to reverse resistance to cancer immunotherapies.

Funding History

2
Total raised:$200M
Venture$150M
Series B$50M

Opportunities

CatalYm's primary growth opportunity lies in establishing visugromab as a foundational combination therapy across multiple solid tumors to overcome checkpoint inhibitor resistance, a large and growing unmet need.
Success in ongoing Phase 2b trials could unlock significant partnership or acquisition interest from large pharma companies.
The platform also has potential expansion into cancer cachexia, a common and debilitating comorbidity in advanced cancer.

Risk Factors

Key risks include clinical trial failure in the critical Phase 2b NSCLC study, emergence of competitive therapies targeting similar resistance pathways, and the ongoing need to secure substantial financing to advance clinical programs as a private, pre-revenue company.

Competitive Landscape

CatalYm appears to be a first-mover in directly targeting GDF-15. Broader competition comes from other approaches to overcome checkpoint inhibitor resistance, including therapies targeting TIGIT, LAG-3, TIM-3, and the adenosine pathway (CD73/CD39). The company's differentiation is its novel mechanism and early clinical data showing durable responses in refractory patients.

More companies in Immunotherapy / Immuno-Oncology →More companies in Germany →